文献速递骨软组织肉瘤与黑色素瘤泌尿男性生殖肿瘤头颈与中枢神经肿瘤

新辅助免疫治疗正在重塑多瘤种癌症管理:未来已来

Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
PubMed 文献 · Eur J Cancer · 2021-06-06

意大利NIBIT基金会2020年线上Think Tank会议汇聚学术、临床、产业、慈善及监管代表,讨论新辅助免疫治疗在皮肤黑色素瘤、肌层浸润性尿路上皮膀胱癌、头颈鳞癌和胰腺导管腺癌中的试验现状。黑色素瘤新辅助免疫治疗取得突破性进展,病理完全缓解、近完全缓解及部分病理缓解可减少90-100%的复发,而靶向治疗中仅pCR似可减少复发。抗CTLA-4联合抗PD1在新辅助黑色素瘤中改变游戏规则,可治愈更多患者、减少复发及淋巴结清扫和转移灶切除需求。

要点

  • 黑色素瘤新辅助免疫治疗的pCR、近pCR及部分病理缓解可减少90-100%复发。
  • 靶向治疗新辅助黑色素瘤试验中仅pCR似与复发减少相关。
  • 抗CTLA-4联合抗PD1新辅助治疗可改变可触及III期或可切除IV期黑色素瘤实践。

核心结论

  • 新辅助免疫治疗在多个瘤种中展现重塑癌症管理的潜力,黑色素瘤进展尤为突出。

研究设计与样本

  • 意大利NIBIT基金会2020年线上Think Tank会议,多领域代表讨论新辅助免疫治疗试验现状。

主要发现

  • 黑色素瘤新辅助免疫治疗后pCR、近pCR及部分病理缓解可减少90-100%的复发。
  • 新辅助靶向治疗黑色素瘤试验中仅pCR似可减少复发。
  • 不同瘤种(黑色素瘤、MIBC、HNSCC、PDAC)新辅助免疫治疗的pCR率不同,可能与复发率下降程度相关。
  • 黑色素瘤中抗CTLA-4联合抗PD1新辅助治疗可治愈更多可触及III期或可切除IV期患者,减少复发及淋巴结清扫和转移灶切除需求。

临床怎么用

  • 可触及III期或可切除IV期黑色素瘤可考虑抗CTLA-4联合抗PD1新辅助免疫治疗。
  • 未来需优化不同瘤种治疗,减少单核细胞(肿瘤相关巨噬细胞)和成纤维细胞(癌相关成纤维细胞)介导的屏障,促进免疫细胞招募、减少免疫抑制介质并增加抗原呈递。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Italian Network for Tumor Biotherapy (Network Italiano per la Bioterapia dei Tumori [NIBIT]) Foundation hosted its annual 2020 Think Tank meeting virtually, at which representatives from academic, clinical, industry, philanthropic, and regulatory organisations discussed the role of neoadjuvant immunotherapy for the treatment of cancer. Although the number of neoadjuvant immunotherapeutic trials is increasing across all malignancies, the Think Tank focused its discussion on the status of neoadjuvant trials in cutaneous melanoma (CM), muscle-invasive urothelial bladder cancer (MIBC), head and neck squamous cell carcinoma (HNSCC), and pancreatic adenocarcinoma (PDAC). Neoadjuvant developments in CM are nothing short of trailblazing. Pathologic Complete Response (pCR), pathologic near Complete Response, and partial Pathologic Responses reduce 90-100% of recurrences. This is in sharp contrast to targeted therapies in neoadjuvant CM trials, where only a pCR seems to reduce recurrence. The pCR rate after neoadjuvant immunotherapy varies among the different malignancies of CM, MIBC, HNSCC, and PDAC and may be associated with different reductions of recurrence rates. In CM, emerging evidence suggests that neoadjuvant immunotherapy with anti-CTLA-4 plus anti-PD1 is a game changer in patients with palpable nodal Stage III or resectable Stage IV disease by curing more patients, reducing recurrences and the need for surgical interventions, such as lymph node dissections and metastasectomies. The Think Tank panel discussed future approaches on how to optimise results across different tumour types. Future approaches should include reducing monocyte-mediated (tumour-associated macrophages) and fibroblast-mediated (cancer-associated fibroblasts) barriers in the tumour microenvironment to facilitate the recruitment of immune cells to the tumour site, to reduce immune-suppressive mediators, and to increase antigen presentation at the site of the tumour.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Maio M, Blank C, Necchi A, et al. Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now! Eur J Cancer. 2021. PMID: 34107449. doi:10.1016/j.ejca.2021.04.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。